TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications

Figure 2

Potential TRAIL-mediated therapeutic approaches to target uveal melanoma cells. Different agents such as radiotherapy, cycloheximide, interferon-beta (IFN-β), class-I specific histone deacetylase inhibitor MS-275, 2-deoxy-D-glucose (2-DG), the glutamate-dependent transaminase inhibitor aminooxyacetate (AOA), and the specific IGF-1R kinase inhibitor cyclolignan picropodophyllin (PPP) may sensitize uveal melanoma cells to TRAIL-mediated apoptosis or enhance TRAIL cytotoxicity. TRAIL-R, TRAIL receptors.